Last reviewed · How we verify
KITE-363
At a glance
| Generic name | KITE-363 |
|---|---|
| Sponsor | Kite, A Gilead Company |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of KITE-363 in Participants With Refractory Autoimmune Diseases (PHASE1)
- A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases (PHASE1)
- Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
- Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KITE-363 CI brief — competitive landscape report
- KITE-363 updates RSS · CI watch RSS
- Kite, A Gilead Company portfolio CI